Breaking News

Charles River Announces Latest Cohort of Its Cell & Gene Therapy Incubator Program

The program aims to expedite the development of technologies and life-changing therapies for patients in need.

Author Image

By: Charlie Sternberg

Associate Editor

Charles River Laboratories International Inc. has announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to scientific and commercial expertise, as well as an ecosystem of discovery, development, and manufacturing capabilities, to expedite the development of technologies and life-changing therapies for patients in need. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters